114 Chapter 4 a small price to pay realizing that the use of biologicals adds up to approximately $100,000 per year of treatment per patient (14, 15). These findings might aid in designing companion diagnostics for targeted therapies directed against MET (Fig. 10), ultimately improving overall survival of patients with cancers subjective to ectodomain shedding. Acknowledgements We thank Dr Marjan van den Brink and for her guidance and critical feedback. The authors also thank past and present members of the Clinical Diagnostics Laboratory at Eli Lilly and Company for technical assistance. Conflict of interest AMG, WZ, and LL are employees of Eli Lilly and Company. Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
RkJQdWJsaXNoZXIy MTk4NDMw